| 0 (0%) | 09-27 14:45 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.44 | 1-year : | 1.69 |
| Resists | First : | 1.24 | Second : | 1.44 |
| Pivot price | 0.85 |
|||
| Supports | First : | 0.82 | Second : | 0.57 |
| MAs | MA(5) : | 0.95 |
MA(20) : | 0.82 |
| MA(100) : | 1.08  |
MA(250) : | 1.33 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 70.2 |
D(3) : | 68.5 |
| RSI | RSI(14): 55.8 |
|||
| 52-week | High : | 3.7 | Low : | 0.57 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ AKTX ] has closed below upper band by 24.0%. Bollinger Bands are 115.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.15 - 1.16 | 1.16 - 1.16 |
| Low: | 0.92 - 0.93 | 0.93 - 0.93 |
| Close: | 0.96 - 0.97 | 0.97 - 0.98 |
Sat, 27 Sep 2025
AKTX Stock Analysis and Forecast - Interest Rate Changes & Free Rapid Return Acceleration - Early Times
Sat, 27 Sep 2025
Akari Therapeutics Reveals Promising Preclinical Data for PH1 - MSN
Wed, 24 Sep 2025
$AKTX stock is up 51% today. Here's what we see in our data. - Quiver Quantitative
Wed, 24 Sep 2025
Akari Therapeutics (AKTX) Reveals Promising Preclinical Data for Prostate Cancer Treatment - GuruFocus
Wed, 24 Sep 2025
Akari Therapeutics’ Preclinical Data Demonstrates the - GlobeNewswire
Wed, 24 Sep 2025
First Potential Treatment for AR-V7 Driven Prostate Cancer: Akari's PH1 Shows Dual Action in Studies - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 33 (M) |
| Shares Float | 11,200 (M) |
| Held by Insiders | 34.2 (%) |
| Held by Institutions | 1.7 (%) |
| Shares Short | 25 (K) |
| Shares Short P.Month | 43 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.79 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.6 % |
| Return on Equity (ttm) | -112.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.4 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | 3 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 1.22 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|